Deciphering IL-17-dependant Inflammatory Response in Bullous Pemphigoid

Launched by CHU DE REIMS · Jun 26, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating the role of a specific protein called IL-17 in the inflammatory response of a skin condition known as Bullous Pemphigoid (BP). BP is a common autoimmune skin disease that primarily affects older adults, causing painful blisters and intense itching. While current treatments like high-potency steroids are effective, they can have significant side effects, especially for elderly patients. The goal of this study is to better understand how IL-17 contributes to the inflammation in BP, which could help researchers develop more targeted and safer treatments in the future.

To participate in this trial, individuals need to be aged between 65 and 74 and have been diagnosed with Bullous Pemphigoid, meeting specific medical criteria. Participants should not have had certain recent treatments or other related conditions that could interfere with the study. Those who join the trial can expect to undergo evaluations and tests to help researchers learn more about this disease and its treatment. This study is actively recruiting participants, and it aims to pave the way for more personalized and effective therapies for those affected by Bullous Pemphigoid.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • patients with Bullous Pemphigoid (BP) using the following criteria: clinical features typical of BP with presence of at least three out of four well-established criteria by Vaillant et al.47; subepidermal blister on skin biopsy; and deposits of IgG and/or C3 in a linear pattern along the epidermal basement membrane zone by direct IF.
• • patient agreed to participate to the study
• • patient affiliated to the French Healthcare System
• Exclusion Criteria:
• • patient that does not have the ability to give its written informed consent before inclusion in the study
• • patient with a pemphigoid gestationis
• • patient with a relapse of Bullous Pemphigoid
• • patient with Bullous Pemphigoid that already received local superpotent corticotherapy during the last 14 days before inclusion or systemic corticoid treatment during the last 28 days before inclusion
• • anemic patient (hemoglobin \< 10 g/dL)